摘要
目的观察地西他滨联合CHG方案诱导化疗由骨髓增生异常综合征转化的急性髓系白血病的疗效和安全性。方法7例新确诊post MDS-AML患者接受地西他滨联合CHG方案诱导化疗。结果4例获完全缓解,1例达到部分缓解,总有效率约为71.42%(5/7)。4例患者出现Ⅳ度骨髓抑制,重度骨髓抑制发生率为57.14%(4/7)。5例并发感染,感染率71.42%(5/7),其中员例治疗无效死亡,化疗相关死亡率14.28%(1/7)。不良反应可见发热及胃肠道反应等。结论地西他滨联合CHG的诱导方案对骨髓增生异常综合征转化的急性髓系白血病有效,且有效率高,严重骨髓抑制是常见并发症,不良反应可以耐受。
Objective To evaluate the induction chemotherapy ef ect and safety of decitabine combined with CHG regime for MDS-transformed acute myeloid leukemia(post MDS-AML).Methods 7 patients with post MDS-AML were treated with decitabine combined with CHG regimen.Results 4 patients achieved complete remission,1patient achieved partial remission,total ef etive rate was 71.42%.4 patients achievedⅣbone marrow depression and the incidence rate of grade Ⅳ bone marrow depression was 57.14%(4/7).5 patients achieved infection,incidence rate of infection was 71.42%(5/7),one of the two infected patients died,which the mortality rate of the treatment 14.28%(1/7).Fever and sickness and was observed as adverse ef ect of the regimen.Conclusion The induction chemotherapy of decitabine combined with CHG regime for MDS-transformed acute myeloid leukemia(post MDS-AML)works ef ectively.The incidence of IV grade bone marrow depression happened of en,and adverse ef ect were light.
作者
易雪
余丹
张婷
邹亮
程辉
YI Xue;YU Dan;ZHANG Ting;ZOU Liang(Wuhan Integrated Tcm and Western Medicine Hospital,Wuhan 430022,Hubei,China)
